Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics (NASDAQ: ABCL) operates at the intersection of biotechnology and drug discovery, making its news feed particularly relevant for investors tracking the antibody therapeutics space. As a platform company that partners with pharmaceutical giants to discover monoclonal antibodies, AbCellera's announcements often signal broader trends in the therapeutics pipeline landscape.
News coverage for ABCL typically centers on partnership announcements and program milestones. When AbCellera discloses new collaborations or reports that partner programs have advanced to new clinical phases, these developments directly impact the company's future milestone and royalty revenue streams. Each clinical trial progression represents both validation of the discovery platform and potential future income.
Quarterly earnings releases reveal how AbCellera's partnership economics translate into financial performance. Beyond headline numbers, these reports detail the status of partner programs, new agreements signed, and updates on the company's proprietary internal pipeline. For a platform-based biotech, understanding the partnership pipeline is essential context.
Clinical trial updates feature prominently in AbCellera's news flow. The company's internal programs generate announcements around trial initiations, interim data readouts, and regulatory interactions. Additionally, positive developments from partner programs—where AbCellera discovered the underlying antibody—often merit disclosure given milestone payment implications.
Patent and intellectual property news matters for platform companies. AbCellera's microfluidic technology represents a core competitive advantage, and developments related to patent protection or technology licensing can affect the company's market position.
Bookmark this page to follow AbCellera's developments as the company advances its antibody discovery platform and expands its therapeutic pipeline.
AbCellera (Nasdaq: ABCL) has announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022, in Toronto, Canada. The presentation will commence at 6:30 a.m. PT (9:30 a.m. ET). A live audio webcast will be available on AbCellera's Investor Relations website, with a replay accessible post-event. AbCellera specializes in leveraging immune system analysis to discover antibodies that can be developed into therapeutic drugs, collaborating with various drug developers to enhance drug development efficiency.
AbCellera (NASDAQ: ABCL) is set to announce its first quarter 2022 financial results on May 10, 2022, at 2:00 PM PT. An earnings conference call will follow the announcement, with a live audio webcast available on AbCellera's Investor Relations website. The company specializes in antibody discovery, collaborating with drug developers to optimize drug development processes. More details will be disclosed during the earnings call.
AbCellera (Nasdaq: ABCL) unveiled data on its innovative T cell engager platform at the AACR 2022 Annual Meeting. The research showcases a diverse range of CD3-binding antibodies for developing bispecific T cell engagers aimed at enhancing cancer therapies. Bo Barnhart, VP of Translational Research, emphasized the potential of these new antibodies to boost the efficacy of oncology treatments. The platform combines rapid screening capabilities with favorable developability properties, reducing engineering risks and enhancing the probability of successful cancer drug development.
AbCellera (Nasdaq: ABCL) reported a total revenue of $375 million for 2021, a 61% increase from $233 million in 2020. The company ended the year with liquidity exceeding $720 million. Key achievements included 26 new program starts, totaling 78 cumulative starts. Net earnings rose to $153 million ($0.56 per share), up from $119 million ($0.53 per share) in 2020. R&D expenses increased to $62 million, reflecting investment in the company's platform. AbCellera also expanded its partner network significantly, increasing programs under contract to 156.
AbCellera (Nasdaq: ABCL) announced its participation in the Truist Securities AI Symposium on March 1, 2022, at 8:20 a.m. Pacific Time. The panel, titled “Integrated Platforms for AI-based Drug Discovery,” will feature executives from the Company discussing groundbreaking advancements in drug development. Interested parties can access a live audio webcast through AbCellera's Investor Relations website, with a replay available afterwards. AbCellera specializes in antibody discovery, partnering with various drug developers to expedite the development process for new treatments.
AbCellera (Nasdaq: ABCL) will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 12:40 p.m. PT. Investors and interested parties can access the live audio webcast on AbCellera's Investor Relations website, with a replay available afterward. AbCellera is a tech company specializing in analyzing immune systems to discover antibodies for drug development, partnering with pharmaceutical and biotechnology firms to streamline processes and address challenges in drug development.
AbCellera (Nasdaq: ABCL) has received Emergency Use Authorization (EUA) from the U.S. FDA for bebtelovimab (LY-CoV1404), its antibody treatment for mild-to-moderate COVID-19 in high-risk patients. Bebtelovimab effectively neutralizes the Omicron variant, including BA.2, demonstrating broad efficacy against circulating SARS-CoV-2 variants. The authorized dosage is 175 mg as an intravenous injection. Additionally, Lilly has contracted to supply up to 600,000 doses to the U.S. government by March 31, 2022, and an option for 500,000 more by July 31, 2022.
AbCellera (Nasdaq: ABCL) has announced a purchase agreement with Eli Lilly for the supply of up to 600,000 doses of the investigational drug bebtelovimab. The deal is valued at a minimum of $720 million and is contingent upon obtaining Emergency Use Authorization from the FDA. Testing confirms that bebtelovimab neutralizes the Omicron variant and its subvariants. This drug is part of AbCellera's rapid response to COVID-19, initiated in 2020, which also led to the development of bamlanivimab.
AbCellera (Nasdaq: ABCL) will report its full year 2021 financial results on February 24, 2022, after market close. The earnings conference call will commence at 2:00 p.m. PT (5:00 p.m. ET), with a live webcast available on AbCellera’s Investor Relations website. The company specializes in antibody development, partnering with various drug developers to enhance drug development efficiency.
AbCellera (Nasdaq: ABCL) announced changes in its Board of Directors, appointing Andrew W. Lo, Ph.D., as an independent director, while John Hamer, Ph.D., resigned. Dr. Lo, known for his innovative financial engineering and machine learning in drug development, will join the Audit and Compensation Committees. CEO Carl Hansen praised Dr. Lo's expertise in connecting financial structures with biomedical innovation. Hamer, who served since 2018, was acknowledged for his valuable contributions. These changes aim to enhance AbCellera's strategic direction in antibody therapy development.
FAQ
What is the current stock price of Abcellera Biologics (ABCL)?
What is the market cap of Abcellera Biologics (ABCL)?
